Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Epidermal Growth Factor Receptor Mutations in Lung Adenocarcinoma in Malaysian Patients

Epidermal Growth Factor Receptor Mutations in Lung Adenocarcinoma in Malaysian Patients ORIGINAL ARTICLE Epidermal Growth Factor Receptor Mutations in Lung  Adenocarcinoma in Malaysian Patients Chong-Kin Liam, MRCP,* Mohamed Ibrahim A. Wahid, MD,† Pathmanathan Rajadurai, FRCPATH,‡ Yoke-Kqueen Cheah, PhD,§ and Tiffany Shi-Yeen Ng, BSc§ Key Words: EGFR mutations, Lung adenocarcinoma, Malaysian. Introduction: Despite available data from other Asian countries, the prevalence of epidermal growth factor receptor (EGFR) muta- (J Thorac Oncol. 2013;8: 766–772) tions among lung adenocarcinoma patients has not been reported in Malaysia. This study sought to determine the frequency of EGFR mutations among multiethnic Malaysian patients diagnosed with denocarcinoma is the most common histologic subtype of lung adenocarcinoma. Anon–small-cell lung cancer in many parts of the world. Methods: Demographic and clinical information of patients whose Many studies have shown epidermal growth factor receptor lung adenocarcinoma biopsy specimens were submitted for EGFR (EGFR) mutations to be associated with improved response 2–4 mutation testing at Sime Darby Medical Center from 2009 to 2011 to treatment with EGFR tyrosine kinase inhibitors (TKIs). were analyzed. EGFR mutations at exons 18, 19, 20, and 21 were EGFR TKIs such as gefitinib and erlotinib inhibit the EGFR detected either through bidirectional sequencing or real-time poly- signaling pathway by acting selectively through competitive merase chain reaction. inhibition of the binding of adenosine triphosphate to the http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Thoracic Oncology Wolters Kluwer Health

Epidermal Growth Factor Receptor Mutations in Lung Adenocarcinoma in Malaysian Patients

Ng, Tiffany Shi-Yeen
Journal of Thoracic Oncology , Volume 8 (6) – Jun 1, 2013
Download PDF
7 pages

Loading next page...
 
/lp/wolters-kluwer-health/epidermal-growth-factor-receptor-mutations-in-lung-adenocarcinoma-in-dH0eoz2po0

References (46)

Copyright
Copyright © 2013 by the International Association for the Study of Lung Cancer
ISSN
1556-0864
DOI
10.1097/JTO.0b013e31828b5228
pmid
23575413
Publisher site
See Article on Publisher Site

Abstract

ORIGINAL ARTICLE Epidermal Growth Factor Receptor Mutations in Lung  Adenocarcinoma in Malaysian Patients Chong-Kin Liam, MRCP,* Mohamed Ibrahim A. Wahid, MD,† Pathmanathan Rajadurai, FRCPATH,‡ Yoke-Kqueen Cheah, PhD,§ and Tiffany Shi-Yeen Ng, BSc§ Key Words: EGFR mutations, Lung adenocarcinoma, Malaysian. Introduction: Despite available data from other Asian countries, the prevalence of epidermal growth factor receptor (EGFR) muta- (J Thorac Oncol. 2013;8: 766–772) tions among lung adenocarcinoma patients has not been reported in Malaysia. This study sought to determine the frequency of EGFR mutations among multiethnic Malaysian patients diagnosed with denocarcinoma is the most common histologic subtype of lung adenocarcinoma. Anon–small-cell lung cancer in many parts of the world. Methods: Demographic and clinical information of patients whose Many studies have shown epidermal growth factor receptor lung adenocarcinoma biopsy specimens were submitted for EGFR (EGFR) mutations to be associated with improved response 2–4 mutation testing at Sime Darby Medical Center from 2009 to 2011 to treatment with EGFR tyrosine kinase inhibitors (TKIs). were analyzed. EGFR mutations at exons 18, 19, 20, and 21 were EGFR TKIs such as gefitinib and erlotinib inhibit the EGFR detected either through bidirectional sequencing or real-time poly- signaling pathway by acting selectively through competitive merase chain reaction. inhibition of the binding of adenosine triphosphate to the

Journal

Journal of Thoracic Oncology – Wolters Kluwer Health

Published: Jun 1, 2013

There are no references for this article.